Literature DB >> 22068705

Establishment of a stable cell line coexpressing dengue virus-2 and green fluorescent protein for screening of antiviral compounds.

V Leardkamolkarn1, W Sirigulpanit.   

Abstract

This study aimed to generate a stable cell line harboring subgenomic dengue virus replicon and a green fluorescent gene (DENV/GFP) for a cell-based model to screen anti-DENV compounds. The gene-encoding envelope protein of DENV-2 was deleted and then replaced with fragments of the GFP gene and a foot-and-mouth-disease virus 2A-derived cleavage site. The human cytomegalovirus immediate early and antisense hepatitis delta virus ribozyme sequences were added at the 5'- and 3'-ends. An internal ribosome entry site and neomycin resistance genes were placed upstream and next to the NS1 gene. The recombinant plasmids were propagated in a mammalian cell line. A stable cell line with the brightest green fluorescent protein and the highest viral protein and RNA expression was selected from six clones. The clone was then examined for effectiveness in an antiviral drug screening assay with compounds isolated from the local plants using two known antiviral agents as controls. Two novel flavones, PMF and TMF, were discovered having DENV-inhibitory properties. The data were validated by a conventional plaque titration assay. The results indicate that this newly developed cell line is efficient for use as a cell-based model for primary screening of anti-DENV compounds.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22068705     DOI: 10.1177/1087057111426903

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  8 in total

1.  Development of Dengue type-2 virus replicons expressing GFP reporter gene in study of viral RNA replication.

Authors:  Vijittra Leardkamolkarn; Wipawan Sirigulpanit; Nunya Chotiwan; Supeecha Kumkate; Claire Y-H Huang
Journal:  Virus Res       Date:  2011-12-16       Impact factor: 3.303

2.  A plasmid-based reporter system for live cell imaging of dengue virus infected cells.

Authors:  Carey L Medin; Sierra Valois; Chinmay G Patkar; Alan L Rothman
Journal:  J Virol Methods       Date:  2014-10-28       Impact factor: 2.014

3.  Discovery of host-targeted covalent inhibitors of dengue virus.

Authors:  Mélissanne de Wispelaere; Margot Carocci; Yanke Liang; Qingsong Liu; Eileen Sun; Michael L Vetter; Jinhua Wang; Nathanael S Gray; Priscilla L Yang
Journal:  Antiviral Res       Date:  2016-12-26       Impact factor: 5.970

4.  Transgene expression in the genome of Middle East respiratory syndrome coronavirus based on a novel reverse genetics system utilizing Red-mediated recombination cloning.

Authors:  Doreen Muth; Benjamin Meyer; Daniela Niemeyer; Simon Schroeder; Nikolaus Osterrieder; Marcel Alexander Müller; Christian Drosten
Journal:  J Gen Virol       Date:  2017-10       Impact factor: 3.891

5.  Green fluorescent protein (GFP) color reporter gene visualizes parvovirus B19 non-structural segment 1 (NS1) transfected endothelial modification.

Authors:  Thomas Wurster; Catharina Pölzelbauer; Tanja Schönberger; Angela Paul; Peter Seizer; Konstantinos Stellos; Andreas Schuster; Rene M Botnar; Meinrad Gawaz; Boris Bigalke
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240

Review 6.  Dengue Virus Reporter Replicon is a Valuable Tool for Antiviral Drug Discovery and Analysis of Virus Replication Mechanisms.

Authors:  Fumihiro Kato; Takayuki Hishiki
Journal:  Viruses       Date:  2016-05-05       Impact factor: 5.048

Review 7.  Live Cell Reporter Systems for Positive-Sense Single Strand RNA Viruses.

Authors:  Linzhu Ren; Zhiyuan Peng; Xinrong Chen; Hongsheng Ouyang
Journal:  Appl Biochem Biotechnol       Date:  2016-01-04       Impact factor: 2.926

8.  Development of a novel DNA-launched dengue virus type 2 infectious clone assembled in a bacterial artificial chromosome.

Authors:  Jose A Usme-Ciro; Jaime A Lopera; Luis Enjuanes; Fernando Almazán; Juan C Gallego-Gomez
Journal:  Virus Res       Date:  2013-12-14       Impact factor: 3.303

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.